Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development anti-angiogenesis therapy cancers improvement its efficacy have been a major focus fundamental clinical research. However, survival benefits current anti-angiogenic agents, such as bevacizumab, patients with are modest. Therefore, better understanding angio...